Artwork

Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Non-Hodgkin Lymphoma | Oncology Today with Dr Neil Love: Chimeric Antigen Receptor T-Cell Therapy in Non-Hodgkin Lymphoma

46:53
 
Share
 

Manage episode 275483784 series 1464173
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Featuring a discussion on recent clinical trial data on the use of CAR T-cell therapy in the management of non-Hodgkin lymphoma with Dr Tanya Siddiqi, including the following topics:

  • CAR T-Cell Therapy in B-Cell Non-Hodgkin Lymphoma — Tanya Siddiqi, MD (00:00)
  • Case: A man in his late 50s with recurrent DLBCL attains complete remission after receiving axicabtagene ciloleucel on the Phase I/II ZUMA-1 trial (32:19)
  • Case: A woman in her mid-60s with relapsed/refractory DLBCL receives lisocabtagene maraleucel on the Phase I TRANSCEND NHL 001 study (36:07)
  • Case: A man in his late 60s with multiple regimen-relapsed CLL receives lisocabtagene maraleucel on the Phase I/II TRANSCEND CLL 004 study (38:34)
  • Tumor lysis syndrome in patients receiving CAR T-cell therapy; FDA regenerative medicine advanced therapy designation for tisagenlecleucel in relapsed/refractory follicular lymphoma (43:08)

CME information and select publications

  continue reading

1343 episodes

Artwork
iconShare
 
Manage episode 275483784 series 1464173
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Featuring a discussion on recent clinical trial data on the use of CAR T-cell therapy in the management of non-Hodgkin lymphoma with Dr Tanya Siddiqi, including the following topics:

  • CAR T-Cell Therapy in B-Cell Non-Hodgkin Lymphoma — Tanya Siddiqi, MD (00:00)
  • Case: A man in his late 50s with recurrent DLBCL attains complete remission after receiving axicabtagene ciloleucel on the Phase I/II ZUMA-1 trial (32:19)
  • Case: A woman in her mid-60s with relapsed/refractory DLBCL receives lisocabtagene maraleucel on the Phase I TRANSCEND NHL 001 study (36:07)
  • Case: A man in his late 60s with multiple regimen-relapsed CLL receives lisocabtagene maraleucel on the Phase I/II TRANSCEND CLL 004 study (38:34)
  • Tumor lysis syndrome in patients receiving CAR T-cell therapy; FDA regenerative medicine advanced therapy designation for tisagenlecleucel in relapsed/refractory follicular lymphoma (43:08)

CME information and select publications

  continue reading

1343 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide